Soleno Therapeutics (SLNO) Given a $4.00 Price Target at Maxim Group

Soleno Therapeutics (NASDAQ:SLNO) has been assigned a $4.00 target price by investment analysts at Maxim Group in a research note issued on Tuesday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target would indicate a potential upside of 143.90% from the stock’s current price.

Other research analysts have also issued reports about the stock. ValuEngine raised shares of Soleno Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. decreased their price target on shares of Soleno Therapeutics from $25.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 15th.

Soleno Therapeutics (NASDAQ SLNO) traded down $0.04 during mid-day trading on Tuesday, hitting $1.64. 47,900 shares of the stock traded hands, compared to its average volume of 99,045. Soleno Therapeutics has a twelve month low of $1.32 and a twelve month high of $4.20. The stock has a market cap of $17.80, a price-to-earnings ratio of -1.03 and a beta of 5.52.

Soleno Therapeutics (NASDAQ:SLNO) last posted its earnings results on Tuesday, November 14th. The company reported ($0.24) earnings per share (EPS) for the quarter. Soleno Therapeutics had a negative return on equity of 54.11% and a negative net margin of 1,389.76%.

In related news, Director Edgar Engleman purchased 1,085,480 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average cost of $1.84 per share, with a total value of $1,997,283.20. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 69.75% of the company’s stock.

An institutional investor recently bought a new position in Soleno Therapeutics stock. Birchview Capital LP purchased a new stake in Soleno Therapeutics Inc (NASDAQ:SLNO) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 678,428 shares of the company’s stock, valued at approximately $1,032,000. Soleno Therapeutics makes up approximately 0.6% of Birchview Capital LP’s holdings, making the stock its 14th biggest holding. Birchview Capital LP owned approximately 6.78% of Soleno Therapeutics at the end of the most recent reporting period.

WARNING: “Soleno Therapeutics (SLNO) Given a $4.00 Price Target at Maxim Group” was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/soleno-therapeutics-slno-given-a-4-00-price-target-at-maxim-group.html.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply